CaaMTech
Preclinical1 active candidate
shared compound: PsilocybinPreclinical peersimilar active pipeline sizeboth have forecast coverage
Back to StakeholdersProgramme tracker View landscape
Lead program: Preclinical
Shortwave Life SciencesAQSE: PSY
CategoriesEarly-Stage Translational Research (Pre-Clinical)Research, Drug Development & Manufacturing
Data updated
1 Drug Candidate
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Shortwave Life Sciences is a UK-listed biopharmaceutical company developing a proprietary psilocybin and beta-carboline buccal film formulation for the treatment of anorexia nervosa. The mucoadhesive film delivery system enables improved bioavailability and rapid onset by bypassing first-pass metabolism, and the company has secured an investigator-initiated Phase 2 clinical trial agreement with Sheba Medical Center in Israel — targeting a condition with no FDA-approved pharmacological treatment.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Shortwave Explains Potential of Psilocybin Therapy for Anorexia
Dec 10, 2025 - industry-media - Psychedelic Health - Psilocybin + Beta-Carboline Buccal Film
Next known catalyst
preclinical-data
Timing not specified - Psilocybin + Beta-Carboline Buccal Film / Psilocybin + Beta-Carboline Buccal Film — Feasibility Study (Anorexia Nervosa) - Confidence: 30%
7 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1Psilocybin + Beta-Carboline Buccal Film
PsilocybinPreclinical
Anorexia nervosa
Eating Disorders
Primary: Other
Pre-clinicalActive
Forecast
preclinical-data
Shortwave continues to position its psilocybin buccal film around an anorexia feasibility study; 2025 coverage says the company is working to show safe delivery and clinical-practice integration.
Milestones
Company milestone
CompletedActual: Jul 1, 2022
Clinical trial agreement signed with Sheba Research Fund and Sheba Center for Eating Disorders for investigator-initiated feasibility study
Why it matters: Sheba Medical Center is Israel's largest hospital and a leading eating disorders research center. The investigator-initiated structure means Sheba sponsors the trial while Shortwave provides drug product and retains commercial rights.
Company milestone
CompletedActual: Jul 1, 2024
PCT patent claims validated for novel mucoadhesive buccal film (novel, non-obvious, industrially applicable)
Why it matters: Patent validation protects the buccal delivery platform. The film combines psilocybin with a beta-carboline (reversible MAO-A inhibitor) to extend psychedelic duration by slowing psilocin metabolism — similar to the ayahuasca mechanism. Buccal delivery also bypasses first-pass metabolism for higher bioavailability.
preclinical-data
CompletedActual: Sep 1, 2024
Positive preclinical safety results: 3 dose groups in rats with no adverse effects observed
Why it matters: Clean preclinical safety profile supports progression to human dosing in the Sheba feasibility study.
Funding milestone
CompletedActual: Jul 1, 2025
Raised GBP 290,000 via private and strategic placements (GBP 40K in June + GBP 250K in July 2025)
Why it matters: Very small raise indicates micro-cap status (AQSE-listed as PSY). Sufficient to fund the Israeli feasibility study but not a larger clinical programme.
Company milestone
CompletedActual: Dec 4, 2025
Dr Nadya Lisovoder presented feasibility study design at PSYCH Symposium
Why it matters: Academic presentation builds credibility and KOL engagement ahead of participant recruitment at Sheba.
Watch next: Feasibility study first patient enrolled; safety and efficacy data from Sheba
Recorded Events
Dec 4, 2025: Company milestone
Jul 1, 2025: Funding milestone
Sep 1, 2024: preclinical-data
Jul 1, 2024: Company milestone
Jul 1, 2022: Company milestone
Evidence Links
Short Wave Pharma to Start Anorexia Nervosa Clinical Trial
industry-media - Labiotech - Jan 1, 2022 - Verified
Coverage describes Shortwave partnership with Sheba for an Israeli Ministry of Health-approved Phase 2 feasibility study.
Sheba Partners with Shortwave Pharma to Test Psilocybin
partner-announcement - Friends of Sheba - Aug 18, 2022 - Verified
Sheba partner announcement supports the psilocybin-assisted psychotherapy anorexia trial and recruitment preparation.
Shortwave Explains Potential of Psilocybin Therapy for Anorexia
industry-media - Psychedelic Health - Dec 10, 2025 - Verified
Recent interview describes Shortwave feasibility study work and buccal film relevance for anorexia nervosa.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Red Light Holland
Preclinical1 active candidate
shared compound: PsilocybinPreclinical peersimilar active pipeline sizeboth have forecast coverage
Psilera
Preclinical3 active candidates1 paper
shared compound: PsilocybinPreclinical peerboth have forecast coverageboth have source coverage
Entropy Neurodynamics
Phase II2 active candidates3 trials
shared compound: Psilocybinsame indication: Eating Disorderssimilar active pipeline sizeboth have forecast coverage
Quick Facts
- Type
- Public Biotech
- Ticker
- AQSE: PSY
- Lead Stage
- Preclinical
- Website
- Visit